Provided by Tiger Fintech (Singapore) Pte. Ltd.

Rexahn Pharmaceuticals

1.81
0.0000
Volume:- -
Turnover:- -
Market Cap:2.00M
PE:-0.29
High:1.81
Open:1.81
Low:1.81
Close:1.81
Loading ...

Company Profile

Company Name:
Rexahn Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's product pipeline include RX-3117, which is in Phase IIa clinical trials for the treatment of patients with relapsed or refractory metastatic pancreatic cancer, as well as bladder, colon, lung and cervical cancer. It is also developing RX-0301, which is in preclinical development stage for the treatment of hepatocellular carcinoma. Rexahn Pharmaceuticals, Inc. has collaboration agreements with Zhejiang Haichang Biotechnology Co., Ltd.; and BioSense Global LLC. The company is headquartered in Rockville, Maryland.